Sanofi signs distribution pact with Cipla for CNS portfolio in India

Sanofi India and Cipla announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category.

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and India-wide network of marketing and sales professionals, distributors, institutions, and market outreach programmes to expand access to these treatments for patients who need them.